

International AIDS Society Industry Liaison Forum

Annual Survey 2014




INTRODUCTION

The Industry Liaison Forum (ILF) Annual Survey 2014 is a compilation of information and feedback from ILF Advisory Group members. The goal of this survey is to assess the progress of the ILF and to absorb criticism in a way that benefits both the partners and the IAS. A total of 13 people, out of 28 who were approached, responded to the survey; this represented a 46% feedback response rate.

QUESTIONS AND RESPONSES


Participation

Participation in the survey was diverse. The most represented group of responders was industry (in particular Bronze Partners who contributed 31% of the answers).



Usefulness of the ILF

Overall, participants rated the usefulness of the ILF in a positive light. Three participants added comments, mostly pointing to the great potential of the ILF to bring industry and non-industry partners together to join in the fight against HIV.



Their comments were as follows:


“The [ILF] model has great potential which has not yet been fully realized. However, the recent changes to structure and focus of [the ILF] should increase the profile and impact of [the ILF].”

“[We] are relatively new to the [ILF] and will be in a better position to comment after a full year of membership. Certainly after our initial experience of the group at the [International AIDS Conference] in Melbourne [in] 2014, it does seem to fit with our needs in terms of representation within the HIV community.”


“There are many misconceptions on all sides (industry, KPs {key populations}, clinicians, policy makers, etc.). The ILF will play a significant role in communication so that all are heard.”

Value of ILF activities


Respondents rated their experiences of various activities organized by the ILF in 2014.




IAS-Industry Consultation: What is industry interested in and how can the IAS support it and benefit? (4 March, Boston, USA) (n=13)




IAS-ILF Symposium at the INTEREST Workshop: Expanding access to viral load monitoring in resource-limited settings (5 May, Lusaka, Zambia) (n=13)




IAS-ILF/CIPHER Thematic Roundtable: Removing barriers and seizing opportunities in paediatric HIV (19 July, Melbourne, Australia) (n=13)



IAS-ILF Advisory Group meeting: Implementing the new IAS-ILF and more (21 July, Melbourne, Australia) (n=13)










IAS-Industry Consultation - Creating synergy: How can the IAS and industry address the challenges in HIV and related co-infections? (22 July, Melbourne, Australia) (n=13)









Interest in ILF activities planned for 2015

Overall, all planned activities for 2015 received fairly positive interest.



Usefulness of different means of interaction and external communication





The usefulness of the different means of communication used by the ILF was evaluated. The use of Twitter did not appear to be useful to respondents; this is explained as Twitter is used for external communications and advocacy, and not for communications with advisory group members.



Value of the ILF Corporate Partnership Programme


This section was only for ILF Corporate Partners (from industry). The three categories within this question included rating the ILF Corporate Partnership Programme overall, rating within the three-tiered approach and corresponding fees, and rating within benefits and recognition.

Agreement opinions



The compliance of the ILF Corporate Partnership Programme with regulations in place for partnerships with industry was evaluated. Out of the seven who responded to this question, five answered with a clear “yes” and two answered with “I don’t know”.

Participants were also asked what their ideal agreement period would be. The majority selected one-year agreements as optimal.




Members in the Corporate Partnership Programme were also asked which of the many benefits offered to them were the most and least important to their companies. Answers are provided in the following table. Participation in the advisory group was systematically listed as one of the most important benefits.

	Gold Partners	Silver Partners	Bronze Partners
Most Important	<ul style="list-style-type: none"> • Participation in the ILF Advisory Group • Use of the IAS-ILF Gold Partner Logo • Participation in the IAS-ILF Thematic Roundtables 	<ul style="list-style-type: none"> • Participation in the ILF Advisory Group • IAS-Industry Consultations • Recognition as sponsor of Roundtable series participated in 	<ul style="list-style-type: none"> • Participation in the ILF Advisory Group • IAS-Industry Consultations • IAS-ILF Thematic Roundtable: can participate in one; send one person; first to receive reports
Least Important	<ul style="list-style-type: none"> • Receive annual ILF reports • Contribute non-commercial material to communications to IAS members • Receive IAS newsletters and e-updates 	<ul style="list-style-type: none"> • One VIP seating ticket at IAS conferences • Price reduction for IAS annual membership for a limited number of IAS-ILF partner staff 	<ul style="list-style-type: none"> • Annual assessment survey • Receive ILF annual report and quarterly ILF newsletter • Invitations to webinars being conducted under IAS Programmes • Receive IAS newsletters and e-updates • Use of IAS-ILF Bronze Partner logo

Knowledge of IAS Programmes

The knowledge of IAS Programmes was also evaluated.



Attendance at conferences, meetings and workshops

The most commonly attended meeting was the Conference on Retroviruses and Opportunistic Infections (CROI). However, the conferences organized by the IAS (i.e., the International AIDS Conference and the IAS Conference on HIV Pathogenesis, Treatment and Prevention) were not included in this survey, although the respondents mentioned they knew these conferences well in a previous question (see page 9).

Most frequently attended	Responses (n=13)
Conference on Retroviruses and Opportunistic Infections (CROI)	7 (54%)
African Society for Laboratory Medicine (ASLM)	4 (31%)
International Conference on AIDS and Sexually Transmitted Infections in Africa (ICASA)	4 (31%)
Joint WHO-UNICEF-UNFPA Meeting with Manufacturers and Suppliers	4 (31%)
European AIDS Clinical Society Conference (EACS)	3 (23%)
Caribbean HIV Conference	2 (15%)
HIV Drug Therapy Glasgow	2 (15%)
Innovation in Diagnostics Development and Delivery	2 (15%)
International Liver Congress (EASL)	2 (15%)
International Workshop on HIV Paediatrics	2 (15%)
International Workshop of HIV Treatment, Pathogenesis and Prevention Research in Resource-poor Settings (INTEREST)	2 (15%)
Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)	2 (15%)
Latin American and Caribbean Forum on HIV/AIDS and Sexually Transmitted Infections (FORO)	2 (15%)
Liver Meeting (AASLD)	2 (15%)
Southern African HIV Clinicians Society (SAHIVSOC)	2 (15%)
Towards an HIV Cure Symposium	2 (15%)
International Conference of Drug Regulatory Authorities	1 (18%)
International Congress on AIDS in Asia and the Pacific (ICAAP)	1 (18%)
International Workshop on HIV Observational Databases (IWHOD)	1 (18%)
Keystone Symposia	1 (18%)

Involvement in other initiatives similar to the ILF

Participants were asked if they were involved in other initiatives similar to the ILF. Of the 13 respondents, four (31%) said “yes”. The initiatives listed were as follows:

- Towards an HIV Cure Initiative
- Forum for Collaborative HIV Research
- Technical Working Groups (at the national level)
- HCV Drug Development Advisory Group.

CONCLUSIONS

In conclusion, the ILF Annual Survey 2014 was conducted to allow members to voice their opinions about the structure, work and current policies of the ILF. The majority of respondents shed a positive light on the ILF.

The opinions of the ILF Advisory Group members expressed here are highly valued and they will be taken into consideration as the ILF progresses.



ACKNOWLEDGEMENTS

ILF Advisory Group members in 2014

Martin Auton §	Switzerland	The Global Fund to Fight AIDS, Tuberculosis and Malaria
John Bannister §	UK	Omega Diagnostics
Linda-Gail Bekker	South Africa	Desmond Tutu HIV Foundation
Chris Beyrer §	USA	Johns Hopkins University
Celia Christie-Samuels	Jamaica	University of the West Indies
Gavin Cloherty §	USA	Abbott
Bryan Cobb	USA	Roche Molecular Systems
Elliott Cowan §	USA	Partners in Diagnostics
Colleen Daniels §	USA	Treatment Action Group
Joel Gallant *	USA	Southwest CARE Center
Manuel Gonçalves §	UK	ViiV Healthcare
John Hackett §	USA	Abbott
Catherine Hankins	The Netherlands	Amsterdam Institute for Global Health and Development
Nicholas Hellmann	USA	Elizabeth Glaser Pediatric AIDS Foundation
Mike Iddon §	UK	Omega Diagnostics
Elly Katabira *	Uganda	Makerere Medical School
Sandra Lehrman	USA	Merck
Francesco Marinucci §	Germany	Symex Partec
Kenneth Mayer §	USA	Fenway Institute
Perry Mohammed	UK	Janssen
Jeffrey Murray §	USA	U.S. Food and Drug Administration
Rahab Mwaniki	Kenya	National Empowerment Network of People Living with HIV/AIDS in Kenya
Heidi Nass *	USA	AIDS Treatment Activists Coalition
Joseph Perriens §	Switzerland	WHO HIV/AIDS Department
Scott Purdon *	UK	ViiV Healthcare
Boris Renjifo *	USA	AbbVie
Jürgen Rockstroh §	Germany	University of Bonn
James Rooney	USA	Gilead Sciences
Paul Schaper §	USA	MSD
Cheryl Smith *	USA	Burkina Foundation
Stefano Vella §	Italy	Istituto Superiore di Sanità

* Left the ILF Advisory Group in 2014

§ Joined the ILF Advisory Group in 2014

IAS Secretariat

Sébastien Morin	Research Officer, Industry Liaison Forum	Switzerland
Owen Ryan	Executive Director	Switzerland

ILF CORPORATE PARTNERS 2014

GOLD PARTNERS



SILVER PARTNERS



BRONZE PARTNERS



Industry Liaison Forum
International AIDS Society
Avenue de France 23
CH-1202 Geneva
Switzerland
Tel: +41 22 710 08 00
ilf@iasociety.org
www.iasociety.org/ilf

